Viewpoint 1

Jemec, Gregor B.E.

doi:10.1111/j.1600-0625.2008.00712_2.x

Cited by 3 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we demonstrate that complete healing of long-lasting HS lesions can be achieved using an empirical, broad-spectrum antimicrobial treatment strategy based on the combination of rifampin, moxifloxacin and metronidazole. This clinical observation is consistent with the microbial pathophysiological hypothesis of HS, where lesions could result from an abnormal relationship between the host and its own skin microflora [19]. The association of HS and Crohn disease has recently raised the issue that HS may also be a ‘barrier disease’ [21], and the low pathogenicity of bacteria associated with HS lesions is consistent with this hypothesis [8].…”

Section: Discussionsupporting

confidence: 79%

“…Various nonexclusive pathophysiological hypotheses have been proposed for HS, including genetic, microbial, hormonal and immunological factors [19], and the different medical therapeutic options that have been used to treat patients, including retinoids, antibiotics, antiandrogens, high-dose zinc salts and recently anti-tumor-necrosis-factor-α treatments, are not satisfactory [20]. In this study, we demonstrate that complete healing of long-lasting HS lesions can be achieved using an empirical, broad-spectrum antimicrobial treatment strategy based on the combination of rifampin, moxifloxacin and metronidazole.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Rifampin-Moxifloxacin-Metronidazole Combination Therapy in Hidradenitis Suppurativa

et al. 2010

View full text Add to dashboard Cite

Background: Antibiotics have been shown to improve hidradenitis suppurativa (HS) patients but complete remission is rare using these treatments. Objective: To assess the efficacy and safety of a combination of oral rifampin, moxifloxacin and metronidazole in long-lasting refractory HS. Methods: We retrospectively studied 28 consecutive HS patients including 6, 10 and 12 Hurley stage 1, 2 and 3 patients, respectively. Complete remission, defined as a clearance of all inflammatory lesions including hypertrophic scars, was the main outcome criterion of the study. Results: Complete remission was obtained in 16 patients, including 6/6, 8/10 and 2/12 patients with Hurley stage 1, 2 and 3, respectively (p = 0.0004). The median duration of treatment to obtain complete remission was 2.4 (range 0.9–6.5) and 3.8 months (range 1.6–7.4) in stage 1 and 2 patients, respectively, and 6.2 and 12 months in the 2 stage 3 patients. Main adverse events of the treatments were gastrointestinal disorders (64% of patients) and vaginal candidiasis (35% of females). Reversible tendinopathy and hepatitis occurred in 4 and 1 patient, respectively. Conclusions: Complete remission of refractory HS can be obtained using broad-spectrum antibiotics and Hurley staging is a prognostic factor of response to the treatment.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Discussionmentioning

confidence: 99%